What is required to deliver practice changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study [0.03%]
如何在肾癌新辅助治疗中开展改变实践的临床试验？国际肾癌新辅助治疗联盟德尔菲研究
Sabrina H Rossi,Toni K Choueiri,Michael Jewett et al.
Sabrina H Rossi et al.
From the desert to the savannah, the future of combined MET-EGFR treatment [0.03%]
从沙漠到草原：联合MET-EGFR治疗的未来方向
M M van den Heuvel
M M van den Heuvel
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes [0.03%]
高容量和低容量转移性雄激素敏感前列腺癌中的BRCA1/2及同源重组修复异常的流行率及其对预后的影响
D Olmos,D Lorente,A Jambrina et al.
D Olmos et al.
Background: Alterations in BRCA1/2 (BRCA) and other homologous recombination repair (HRR) genes have a negative impact on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Poly(adenosine d...
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study [0.03%]
萨沃利替尼联合奥希替尼治疗因使用奥希替尼进展的表皮生长因子受体突变的非小细胞肺癌伴 MET 高表达和/或扩增患者Ⅱ期 SAVANNAH 研究主要结果分析
F de Marinis,T M Kim,L Bonanno et al.
F de Marinis et al.
Background: MET-based resistance following osimertinib treatment for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) is common. We report the primary analysis of the phase II SA...
Reply to Letter to the Editor "Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study" by Liu et al., G. Rocco, and Szarpak et al [0.03%]
刘等人、G.罗科和Szarpak等发表的题为“电子鼻分析呼出气检测肺癌：多中心前瞻性外部验证研究”的信函的回复
A I G Buma,M B Muntinghe-Wagenaar,V van der Noort et al.
A I G Buma et al.
A-C Hardy-Bessard,E Pujade-Lauraine,R G Moore et al.
A-C Hardy-Bessard et al.
Background: The combination of immunotherapies and poly (ADP-ribose) polymerase inhibitors (PARPis) has been hypothesized to improve outcomes in advanced ovarian cancer (aOC). The FIRST/ENGOT-OV44 trial evaluated adding d...
Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial [0.03%]
恩fortumab vedotin联合派姆单抗治疗初治局部晚期或转移性尿路上皮癌：EV-302/KEYNOTE-A39三期临床试验的中位随访2.5年的结果
T B Powles,M S Van der Heijden,Y Loriot et al.
T B Powles et al.
Background: At the primary analysis of the EV-302 trial, enfortumab vedotin plus pembrolizumab (EV+P) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and o...
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis [0.03%]
avelumab联合sacituzumab govitecan与单药avelumab一线维持治疗晚期尿路上皮癌的疗效：JAVELIN Bladder Medley中期分析
J Hoffman-Censits,M Tsiatas,P M-H Chang et al.
J Hoffman-Censits et al.
Background: Avelumab first-line maintenance is a recommended treatment option for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without progression following platinum-based chemotherapy (PBC)....
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial [0.03%]
恩杂鲁胺联合镭-223治疗转移性去势抵抗性前列腺癌：EORTC 1333/PEACE-3试验的结果
B Tombal,A Choudhury,F Saad et al.
B Tombal et al.
Background: The EORTC 1333 'PEACE-3' study investigated the combination of enzalutamide and 6 monthly injections of radium-223 (Ra223) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone meta...
Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial [0.03%]
伊马替尼治疗的晚期胃肠道间质瘤二十年生存率——BFR14研究探索性长期随访结果
J-Y Blay,Q Devin,M Toulmonde et al.
J-Y Blay et al.
Background: Gastrointestinal stromal tumors (GIST) are driven in >75% of patients by mutations in KIT and PDGFRA kinases. Imatinib, a tyrosine kinase inhibitor, has shown efficacy in metastatic GIST but the long-term surv...